Preimplantation Genetic Testing for Aneuploidy (PGT-A) in Women Aged 37-41 Years
Condition(s) studied
Investigational drug(s) / intervention(s)
PGT-A: PGT-A is a technique that allows for the prediction of embryo ploidy status through analysis of a trophectoderm biopsy conducted prior to embryo transfer.
Study summary
A multinational multi-centre, randomized, controlled non-blinded trial with participation of three fertility clinics in Denmark and one in Spain to assess the efficacy and safety of preimplantation genetic testing for aneuploidy (PGT-A) in 37-41-year-old women.
Eligibility
Primary outcome measure(s)
- Live birth rate per first embryo transfer — Approximately 12 months after inclusion of the last patient
To assess if PGT-A is superior to standard non-PGT-A treatment regarding the live birth rate per first embryo transfer (ET) (or no ET if only aneuploid embryo(s) in the PGT-A group) per randomized woman. - Cumulative live birth rate after one complete ART treatment — Approximately 18 months after inclusion of the last patient
To assess if PGT-A is non-inferior compared to standard treatment regarding the cumulative LBR after one complete ART treatment per randomized woman.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Rigshospitalet | København Ø | Denmark | Recruiting |
More Copenhagen University Hospital, Rigshospitalet trials in Denmark
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06358547 on ClinicalTrials.gov ↗ ← All trials in Denmark